[1] Havlickova B,Czaika VA,Friedrich M.Epidemiological trends in skin mycoses worldwide[J].Mycoses,2008,51(Suppl 4):2-15.
[2] Claus S,Jean-Philippe B,Bernard M.Updates on the Epidemiology of Dermatophyte Infections[J].Mycopathologia,2008,166(5-6):335-352.
[3] Larry EM.Current concepts in systemic and topical therapy for superficial mycoses[J].Clinics in Dermatology,2010,28(2):212-216.
[4] 张建中.几种新的外用糖皮质激素[J].中国药物应用与监测,2005,2(5):30-33.
[5] Lauermua AL,Surber C,Maibach HI.Absorption of topical tacrolimus ointment for atopic dermatitis (FK506) in vitro through human skin:comparisnon with cyclosporin A[J].Skin Pharmacol,1997,10(5-6):230-234.
[6] Clinical and Laboratory Standards Institute.Reference method for broth dilution antifungal susceptibility testing of filamentous fungi;Approved standard.Document M38-A2[S].CLSI,Wayne,PA,USA,2008.
[7] Clinical and Laboratory Standards Institute.Reference method for broth dilution antifungal susceptibility testing of yeasts;Approved standard.M27-A3[S].CLSI,Wayne,PA,USA,2008.
[8] Zhang J,Silao FG,Bigol UG,et al.Calcineurin is required for pseudohyphal growth,virulence,and drug resistance in Candida lusitaniae [J].PLoS One,2012,7:e44192.
[9] Sun S,Li Y,Guo Q,et al.In vitro interactions between tacrolimus and azoles against Candida albicans determined by different methods[J].Antimicrob Agents Chemother,2008,52(2):409-417.
[10] Shirazi F,Kontoyiannis DP.The calcineurin pathway inhibitor tacrolimus enhances the in vitro activity of azoles against Mucorales via apoptosis[J].Eukaryot Cell,2013,12(9):1225-1234.